拜瑞妥(利伐沙班)可以治好静脉血栓吗？

The main ingredient of the tablet is rivaroxaban, which is a red film-coated tablet that is clinically used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). The recommended dose of Xarelto (Rivaroxaban) is 10 mg of Xarelto taken orally once daily. If the wound has stopped bleeding, the medication should be administered between 6-10 hours after surgery.

The four RECORD1-4 studies of Rivaroxaban to prevent VTE after total hip and knee replacement are a series of randomized, double-blind, multi-center clinical trials. The RECORD1-2 study evaluated the safety and effectiveness of Xarelto in preventing VTE in patients undergoing elective total hip replacement surgery. The results showed that compared with enoxaparin, Xarelto could significantly reduce the incidence of total VTE, major VTE and symptomatic VTE, while the incidence of major bleeding events and other bleeding events was similar in the two groups. The RECORD3~4 study compared the safety and effectiveness of the above two drugs in preventing venous thromboembolism in patients after elective total knee replacement. The incidence rate of the primary endpoint event in the enoxaparin group was 18.9%, while that of Xarelto was only 9.6%. The difference between the two was statistically significant (P<0.001). The results showed that the efficacy of the Xarelto (Rivaroxaban) group was not inferior to traditional treatment, and the risk of bleeding was equivalent to or lower than traditional treatment.

Due to the pharmacodynamic properties of Rivaroxaban, overdose may result in bleeding complications. At the same time, some subgroups of patients are at higher risk of bleeding, such as patients with liver damage and kidney damage. After initiation of treatment, these patients should be monitored closely for signs of bleeding complications.